Direct thrombin inhibitors in percutaneous coronary intervention. Bivalirudin;Inhibidores directos de la trombina en el intervencionismo coronario percutáneo. Bivalirudina

Revista Espanola de Cardiologia Suplementos

Volumn 6, Issue H, 2006, Pages

  Cequier, Ángel ^a,b   Maristany, Jaume ^a   Gómez Hospital, Joan Antoni ^a   Iráculis, Emili ^a   Jara, Francesc ^a   Esplugas, Enric ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Bivalirudin; Direct thrombin inhibitors; Glycoprotein IIb IIIa inhibitors; Heparin; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ARGATROBAN; CLOPIDOGREL; DABIGATRAN; DESULFATOHIRUDIN; EFEGATRAN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; HIRULOG; INOGATRAN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; THROMBIN INHIBITOR; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; META ANALYSIS; MONOTHERAPY; MORTALITY; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZATION; REVIEW; RISK REDUCTION; ST SEGMENT ELEVATION; SYSTEMATIC REVIEW; THROMBOGENESIS;

EID: 35948991873     PISSN: 11313587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1131-3587(06)74841-5     Document Type: Article

References (47)

1. Weitz JI, Bates SM. Beyond heparin and aspirin: new tratments for unstable angina and non-Q-wave myocardial infarction. Arch Intern Med. 2000;160:749-58.
2. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-71.
3. Boersma E. Direct thrombin inhibitors in acute coronary syndrome patients undergoing percutaneous coronary intervention: special effects in selected patients? Eur Heart J. 2005;26:2354-5.
4. Gurm HS, Bhatt DL. Thrombin, an ideal target for pharmacological inhibition: A review of direct thrombin inhibitors. Am Heart J. 2005;149:S43-53.
5. Waller BF. Early and late morphologic changes in human coronary arteries after percutaneous transluminal coronary angioplasty. Clin Cardiol. 1983;6:363-72.
6. Bates SM, Weitz JI. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am J Cardiol. 1998;82:P12-8.
7. Weitz Jl, Bates ER. Direct thrombin inhibitors in cardiac disease. Cardiovasc Toxicol. 2003;3:13-25.
8. Soward AL, Essed CE, Serruys PW. Coronary arterial findings after accidental death immediately after successful percutaneous transluminal coronary angioplasty. Am J Cardiol. 1985;56:794-5.
9. Hirsh J. Heparin. N Engl J Med. 1991;324:1565-74.
10. Becker R, Butenas S, Carr M. Bivalirudin, thrombin and platelets: clinical implications and future directions. J Invasive Cardiol. 2003;Suppl:1-15.
11. Eriksson BI, Dahl OE. Prevention of venoues thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors. Drugs. 2004;64:577-95.
12. Gandossi E, Lunven C, Gauffeny C. Platelet aggregation induced in vitro by rabbit plasma clot-associated thrombin, and its inhibition by thrombin inhibitors. Thromb Haemost. 1998;80:840-4.
13. White CM. Thrombin-directed inhibitors: pharmacology and clinical use. Am Heart J. 2005;149:S54-60.
14. Bode W, Stubbs MT. Spatial structure of thrombin as a guide to its multiple sites of interaction. Semin Thromb Hemost. 1993;19:321-33.
15. Stubbs MT, Bode W. A player of many parts: the spotlight falls on thrombin's structure. Thromb Res. 1993;69:1-58.
16. Di Nisio M, Middeldorp S, Büller HR. Direct thrombin inhibitors. N Engl J Med. 2005;353:1028-40.
17. Lewis BE, Wallis DE, Berkowitz SD. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103:1838-43.
18. Eriksson BI, Dahl OE, Büller HR. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2001;3:103-11.
19. Wallentin L, Wilcox RG, Weaver WD. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomized controlled trial. Lancet. 2003;362:789-97.
20. Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with nonvalvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet. 2003;362:1691-8.
21. Albers GW, Diener HC, Frison L. Ximelagatran vs warfarin for stroke prevention in patients with non-valvular atrial fibrillation: a randomized trial. JAMA. 2005;293:690-8.
22. Colwell CWJr, Berkowitz SD, Davidson BL. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement: a randomized, double-blind study. J Thromb Haemost. 2003;1:2119-30.
23. Lubenow N, Eichler P, Lietz T, Farner B, Greinacher A. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia:an analysis of 3 prospective studies. Blood. 2004;104:3072-7.
24. Parry MA, Maraganore JM, Stone SR. Kinetic mechanism for the interaction of Hirulog with thrombin. Biochemistry. 1994;33:14807-14.
25. Moen MD, Keating GM, Wellington K. Bivalirudin. A review of its use in patients undergoing percutaneous coronary intervention. Drugs. 2005;65:1869-91.
26. The Direct Thrombin Inhibitors Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients data. Lancet. 2002;359:294-302.
27. Boersma E. Direct thrombin inhibitors in acute coronary syndrome patients undergoing percutaneous coronary intervention: special effects in selected patients? Eur Heart J. 2005;26:2354-5.
28. Van den Bos AA, Deckers JW, Heyndickx GR. Safety anf efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation. 1993;88:2058-66.
29. Rupprecht HJ, Terres W, Ozbek C. Recombinant hirudin (HBW 023) prevents troponin T release after coronary angioplasty in patients with unstable angina. J Am Coll Cardiol. 1995;26:1637-42.
30. Serruys PW, Herrman JP, Simon R, Rutsch W, Bode C, Laarman GJ, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl J Med. 1995;333:757-63.
31. Lewis BE, Matthai WH Jr, Cohen M. Argatroban anticoagulation during percutaneous coronary inervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Inter. 2002;57:177-84.
32. Sakai K, Oda H, Honsako A. Obstinate thrombosis during percutaneous coronary intervention in a case with heparin-induced thrombocytopenia. Catheter Cardiovasc Inter. 2003;59:351-4.
33. Imanishi T, Arita M, Tomobuchi Y. Effects of locally administered argatroban on restenosis after balloon angioplasty: experimental and clinical study. Clin Exp Pharmacol Physiol. 1997;24:800-6.
34. Sinnaeve PR, Simes J, Yusuf S, Garg J, Metha S, Eikelboom J, et al. Direct thrombin inhibitors in acute coronary syndomes: effect in patients undergoing early percutaneous coronary intervention. Eur Heart J. 2005;26:2396-403.
35. Bittl JA, Strony J, Brinker JA. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med. 1995;333:764-9.
36. Bittl JA, Chaitman BR, Feit F. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 2001;142:952-9.
37. Lincoff AM, Kleiman NS, Kottke-Marchant K, Maierson ES, Maresh K, Wolski KE, et al. Bivalirudin with planned or provisonal abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J. 2002;143:847-53.
38. Lincoff AM, Bittl JA, Kleiman NS, Sarembock IJ, Jackman JD, Metha S, et al. Comparison of Bivalirudin Versus Heparin During Perecutaneous Coronary Intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events-REPLACE-1 Trial). Am J Cardiol. 2004;93:1092-6.
39. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein iib/iiia blockade during percutaneous coronary intervention. REPLACE-2 Randomized Trial. JAMA. 2003;289:853-63.
40. Ebrahimi R, Lincoff AM, Bittl JA, Chew D, Wolski K, Wadhan N, et al. Bivalirudin versus heparin in percutaneous coronary intervention: a pooled analysis. J Cardiovasc Pharmacol. Ther. 2005;10:209-16.
41. Gurm HS, Sarembock IJ, Kereiakes DJ, Young JJ, Harrington RA, Kleiman N, et al. Use of Bivalirudin During Percutaneous Coronary Intervention in Patients With Diabetes Mellitus. An Analysis from the Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 Trial. J Am Coll Cardiol. 2005;45:1932-8.
42. Chew DP, Bhatt DL, Kimball W. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am J Cardiol. 2003;92:919-23.
43. Chew DP, Lincoff AM, Gurm H. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal i mpairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol. 2005;95:581-5.
44. Mahaffey KW, Lewis BE, Wildermann NM. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol. 2003;15:611-6.
45. Cheneau E, Canos D, Kuchulakanti PK, Rha S, Satler LF, Suddath WO. Value of Monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary intervention. Am J Cardiol. 2004;94:789-792.
46. Stone GW, McLaurin BT, Ware JH, Cox DA, White HD, Bertarnd ME, et al. Prospective, randomized comparison of heparin plus IIb/IIIa inhibition and bivalirudin with or without Iib/IIIa inhibition in patients with acute coronary syndromes: the ACUITY trial. Late-Breaking Clinical Trials I. March 12, 2006. American College Cardiology Congress. Atlanta 2006.
47. Stone GW, Cox DA, Pocock JP, McLaurin BT, Feit F, Colombo A, et al. Prospective, randomized comparison of routine upfront initiation vs selective use of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes: The ACUITY Timing trial. 12 Summit 2006 Late Breaking Clinical Trials II. March 13, 2006. American College Cardiology Congress. Atlanta 2006.